SNY News and Press, Sanofi From 02/20/26

2026-02-20 07:41:55 ET More on Sanofi Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript Sanofi 2025 Q4 - Results - Earnings Call Presentation Sanofi replaces CEO Paul Hudson, names ...

2026-02-19 14:10:21 ET More on Pfizer, Sanofi, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) China drug lic...

2026-02-19 13:31:04 ET More on AbbVie, AstraZeneca PLC, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable AbbVie: Dominating Immunology While Building Oncology Upside Merck posts n...

2026-02-19 12:44:15 ET More on Sanofi, Mercedes-Benz Group AG, etc. Mercedes-Benz Group AG (BENZ:CA) Q4 2025 Earnings Call Prepared Remarks Transcript Mercedes-Benz Group AG 2025 Q4 - Results - Earnings Call Presentation Sanofi: CEO Leaves With Project Rejuvenation U...

2026-02-18 14:13:52 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction ...

2026-02-18 08:45:56 ET One Million Transgenic Silkworms Being Deployed as Production Targets 10 Metric Tons per Month Denver, Colorado-- Kraig Biocraft Laboratories (OTCQB:KBLB) (“the Company” or “Kraig Labs”), the undisputed global leader in the deve...

2026-02-18 08:16:36 ET Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company focused on developing novel immunology therapies for autoimmune and chronic inflammatory diseases, founded in 1990. The company utilizes proprietary technology platforms, including PEGylation...

Sanofi announces leadership evolution in Specialty Care Business Unit PR Newswire CAMBRIDGE, Mass. , Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who ...

2026-02-17 06:15:51 ET Read the full article on Seeking Alpha For further details see: Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease

2026-02-17 04:07:05 ET More on Sanofi Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript Sanofi 2025 Q4 - Results - Earnings Call Presentation Sanofi replaces CEO Paul Hudson, names ...